Union Budget 2025: Pharma industry applauds key provisions on drug accessibility, R&D boost
Budget provisions focus on customs duty exemptions, R&D funding, and healthcare infrastructure expansion
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Budget 2025
Exemptions, concessional duty on essential medicines to improve drug access: Sudarshan Jain, IPA
Sudarshan Jain, Secretary General of Indian Pharmaceutical Alliance (IPA) opines that by prioritising drug accessibility, robust…
Some gaps in Union Budget 2025, but positive policy-level clarifications: Anil Matai, OPPI
Anil Matai, Director General, OPPI observes that while some gaps remain, OPPI is committed to facilitating and partnering with the…
Budget expectations: Leaders opine for incentives in the nutra and API manufacturing sectors
Industry players urge the government to prioritise funding for research into botanical herbs and address the challenge of API…
Bolstering India’s healthcare innovation in cancer, rare diseases: How Budget 2025 can make a…
Amit Mookim, CEO, Immuneel Therapeutics urges the govt to focus on establishing a strong compliance framework and expediting…